Biogen (BIIB) Tops Q3 EPS by 66c, Updates FY Guidance
Tweet
Share
E-mail
Get Alerts BIIB Hot Sheet
Price: $210.65 +0.85%
Financial Fact:
Restructuring charge: 11.6M
Today's EPS Names:
OFLX, VAXX, NMRD, More
Financial Fact:
Restructuring charge: 11.6M
Today's EPS Names:
OFLX, VAXX, NMRD, More
Join SI Premium – FREE
Biogen (NASDAQ: BIIB) reported Q3 EPS of $4.77, $0.66 better than the analyst estimate of $4.11. Revenue for the quarter came in at $2.78 million versus the consensus estimate of $2.67 million.
GUIDANCE:
Biogen sees FY2021 EPS of $18.85-$19.35, versus the consensus of $18.61. Biogen sees FY2021 revenue of $10.8-10.9 billion, versus the consensus of $10.76 billion.
For earnings history and earnings-related data on Biogen (BIIB) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Wolfe Research Upgrades Biogen (BIIB) to Outperform
- Lument Finance Trust (LFT) Misses Q2 EPS by 17c
- CaliberCos Inc (CWD) Misses Q2 EPS by 43c; Offers Guidance
Create E-mail Alert Related Categories
Earnings, Guidance, Hot EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
